A study on the efficacy of recombinant human endostatin combined with apatinib mesylate in patients with middle and advanced stage non-small cell lung cancer.

A study on the efficacy of recombinant human endostatin combined with apatinib mesylate in patients with middle and advanced stage non-small cell lung cancer. J BUON. 2019 Nov-Dec;24(6):2267-2272 Authors: Zhao J, Yu H, Han T, Wang W, Tong W, Zhu X Abstract PURPOSE: To explore the clinical efficacy of recombinant human endostatin combined with apatinib mesylate in patients with middle and advanced non-small cell lung cancer (NSCLC). METHODS: A total of 64 patients with middle and advanced NSCLC were randomly divided into the control group (n=32) and observation group (n=32). The patients in control group received paclitaxel monotherapy, while those in the observation group were treated with recombinant human endostatin combined with apatinib mesylate. The short-term efficacy, the lung function and levels of immunoglobulin and T lymphocyte subsets before and after treatment and the adverse drug reactions of patients were compared between the two groups. All patients were followed up for 5 years, and the survival rate in the two groups was observed. RESULTS: The short-term efficacy and lung function in observation group were better than those in control group (p
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research

Related Links:

Publication date: Available online 9 October 2020Source: PhytomedicineAuthor(s): Jian-Shu Lou, Li-Ping Zhao, Zhi-Hui Huang, Xia-Yin Chen, Jing-Ting Xu, William Chi-Shing TAI, Karl W.K. Tsim, Yi-Tao Chen, Tian Xie
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
Authors: Han AR, Lee S, Han S, Lee YJ, Kim JB, Seo EK, Jung CH Abstract Radiotherapy using ionizing radiation is a major therapeutic modality for advanced human lung cancers. However, ionizing radiation itself can induce malignant behaviors such as cancer cell migration and invasion, leading to local recurrence or distal metastasis. Therefore, safer and more effective agents that inhibit the metastatic behaviors of cancer cells in radiotherapy are needed. As a part of our ongoing search for new radiotherapy enhancers from medicinal herbs, we isolated the following triterpenoids from the ethanol extract of Centella ...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Publication date: Available online 8 October 2020Source: European Journal of RadiologyAuthor(s): Tao Yu
Source: European Journal of Radiology - Category: Radiology Source Type: research
Publication date: Available online 8 October 2020Source: The Annals of Thoracic SurgeryAuthor(s): Jean-Baptiste Leclère, Ludovic Fournel, Harry Etienne, Charbel Al Zreibi, Ilaria Onorati, Arnaud Roussel, Yves Castier, Emmanuel Martinod, Françoise Le Pimpec-Barthes, Marco Alifano, Jalal Assouad, Pierre Mordant, thoracic surgery units of Paris Public Hospitals.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Condition:   Lung Cancer, Non-Small Cell Interventions:   Drug: Dostarlimab;   Drug: Pembrolizumab;   Drug: Chemotherapy Sponsor:   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: Aaptamine retarded the proliferation and invasion of NSCLC cells by selectively targeting the pathway PI3K/AKT/GSK3β suggesting it as a potential chemotherapeutic agent for repressing tumorigenesis and progression of NSCLC in humans. PMID: 33027592 [PubMed - in process]
Source: Pharmaceutical Biology - Category: Drugs & Pharmacology Tags: Pharm Biol Source Type: research
Conclusion: As far as we know, this study will be the first meta-analysis to compare the efficacy of the vein-first and artery-first surgical technique of segmentectomy for patients diagnosed with resectable non–small cell lung cancer. Due to the nature of the disease and intervention methods, RCTs may be inadequate, and we will carefully consider inclusion in high-quality, non-RCTs, but this may result in high heterogeneity and affect the reliability of the results. INPLASY registration number: INPLASY202080062
Source: Medicine - Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research
Rationale: Anlotinib has been proved to be effective in advanced refractory non-small cell lung cancer. Patient concerns: A 47-year-old female non-smoker was admitted due to persistent chest tightness for a month. Diagnoses: Epidermal growth factor receptor (EGFR) wild-type advanced primary lung adenocarcinoma without brain or bone metastasis. Interventions: The patient failed 2 lines of pemetrexed/docetaxel plus carboplatin and third-line erlotinib. Fourth-line anlotinib was administered thereafter. Outcomes: The pulmonary lesions showed partial remission 5 months after anlotinib monotherapy. The patient dem...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
ConclusionIn proton-based 4D Robust SBRT, the interplay effects degraded the target dose distribution but were mitigated using iso-energy layer repainting techniques. However, there was no significant correlation between the number of repainting layers and improvements in the dose distributions. The optimal layer repainting times based on the interplay effect index were ascertained according to the patient characteristics.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer | Study